A Structured Interview Evaluating Botulinum Toxin Type A Treatments for blepharospasm (P4.328)

CONCLUSIONS: Patients showed most satisfaction at maximum effect and preferred injection intervals less than the standard 12 weeks. JRS and BSDI results indicated patients continued to have symptoms. Studies are warranted to confirm the time course of patient satisfaction and determine optimal dosing interval. Study Supported by: Merz North America, Inc.Disclosure: Dr. Sethi has received personal compensation for activities with Synosia, Lundbeck Research USA, Inc., Auspex Pharmaceuticals, Veloxis Pharmaceuticals, Adamas Pharmaceuticals, Impax Laboratories, Teva Neuroscience, and US WorldMeds as a consultant and/or Dr. Fezza has received personal compensation for activities with Merz North America, Inc. as a consultant. Dr. Burns has received personal compensation for activities with Merz North America as a consultant. Dr. Woodward has received personal compensation for activities with Merz Pharma as a consultant and/or speaker. Dr. Truong has received personal compensation for activities with Ipsen, Allergan, Inc., Schering-Plough, and Novartis as a consultant. Dr. Hedges has nothing to disclose. Dr. Taupin has received personal compensation for activities with Merz Pharma as an employee. Dr. Verma has received personal compensation for activities with Merz Pharma as an employee.

Source: Neurology - April 8, 2015 Category: Neurology Authors: Sethi, K., Fezza, J., Burns, J., Woodward, J., Truong, D., Hedges, T., Taupin, P., Verma, A. Tags: Movement Disorders: Dystonia Source Type: research